79183-19-0

Usage

Uses

1. Used in Pharmaceutical Industry:
1-(3,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE is used as an apoptosis activator for its ability to activate caspases in a cytochrome c-dependent manner, inducing apoptosis in tumor cells. This selective targeting of cancer cells makes it a promising candidate for the development of novel anticancer drugs.
2. Used in Cancer Research:
In the field of cancer research, 1-(3,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE is utilized for its potential to activate apoptosis in cancer cells, demonstrating selectivity against normal cell lines. This selective action allows for the development of targeted therapies with minimal side effects on healthy cells.
3. Used in Drug Delivery Systems:
Similar to gallotannin, 1-(3,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE can also be incorporated into drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. The development of novel carriers, such as organic and metallic nanoparticles, can improve the efficacy of 1-(3,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE in treating various types of cancer.

Biological Activity

Apoptosis activator; promotes the cytochrome c-dependent oligomerization of Apaf-1 into the mature apoptosome. Increases procaspase-9 processing and subsequent caspase-3 activation. Induces apoptosis in tumor cells (IC 50 = 4-9 μ M for leukaemia cells) with weak or no effect on normal cell lines or those defective/deficient in Apaf-1, caspase-9 or caspase-3 activity (IC 50 > 40 μ M).

references

[1] nguyen jt, wells ja. direct activation of the apoptosis machinery as a mechanism to target cancer cells. proc natl acad sci u s a. 2003 jun 24;100(13):7533-8.[2] nguyen tv, jayaraman a, quaglino a, pike cj. androgens selectively protect against apoptosis in hippocampal neurones. j neuroendocrinol. 2010 sep;22(9):1013-22.

InChI:InChI=1/C15H9Cl2NO2/c16-11-6-5-9(7-12(11)17)8-18-13-4-2-1-3-10(13)14(19)15(18)20/h1-7H,8H2

Upstream product

• 91-56-5 indole-2,3-dione 
• 102-47-6 3,4-Dichlorophenylmethyl chloride 

Relevant academic research and scientific papers

Synthesis of an indoloquinoxaline derivative as potential inhibitor of InhA enzyme of mycobacterium tuberculosis

Seven heterocyclic compounds derived from isatin have been synthesized. Isatin was Nsubstituted with four aromatic/aliphatic and benzylic moieties (1a-d). Compounds 1a-c were condensed with o-phenylenediamine to afford indoloquinoxaline derivatives (2a-c). Products were tested as inhibitors of InhA enzyme of M. tuberculosis. Compound 6-(diethylaminoethyl)indoloquinoxaline (2a) inhibited 38% of InhA activity at 50 μM. The possible modes of interaction of 2a with InhA were explored by molecular docking. Docking experiments afford keys to improve compound 2a for the design of new potential active drugs against tuberculosis.

Small molecule modulators of apoptosis

The present invention provides methods of identifying modulators of apoptosis. Additionally provided are methods of contacting a cell with a compound capable of decreasing the amount of cyto c necessary to form apoptosome, and thereby inducing apoptosis in and pharmaceutically acceptable derivatives thereof, wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutically compositions thereof, and methods for the use thereof as modulators of apoptosis and for the treatment of disorders caused by excessive or insufficient apoptotic activity.

1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones

The invention concerns novel 1'-substituted spiro[imidazolidine-4,3'-indoline]-2,2',5-triones of the formula: STR1 in which R1 is (1-12C)alkyl; phenyl, naphthylmethyl or cinnamyl optionally bearing 1-2 halogeno substituents; or benzyl optionall

Spiro [imidazolidine 4,3'-indoline]2,2',5-triones, compositions and use

The invention provides novel non-toxic biodegradable derivatives of the formula: STR1 wherein Ra is (1-12C)alkyl, phenyl, naphthylmethyl or cinnamyl, the aromatic rings of which optionally bear one or two halogeno substituents, or Ra is benzyl optionally bearing up to 3 substituents independently selected from halogeno, trifluoromethyl, (1-4C)alkyl, (1-4C)alkoxy, nitro, cyano and hydroxy; Rb and Rc are independently selected from hydrogen and non-toxic biodegradable protecting radicals, but are not both hydrogen; and benzene ring A optionally bears one substituent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy, nitro and hydroxy, or bears two substituents independently selected from halogeno, (1-4C)alkyl and nitro; pharmaceutical compositions thereof; and processes for their manufacture. The amides of formula I in which Rb=Rc=H are potent inhibitors of the enzyme aldose reductase. The derivatives of formula I provided by the invention are of use in vivo in the treatment or prophylaxis of certain complications of diabetes or galactosemia.